Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer.

Cuenca-López MD, Serrano-Heras G, Montero JC, Corrales-Sánchez V, Gomez-Juarez M, Gascón-Escribano MJ, Morales JC, Voisin V, Núñez LE, Morís F, Bader GD, Pandiella A, Ocaña A.

Oncotarget. 2015 Sep 29;6(29):27923-37. doi: 10.18632/oncotarget.4736.

2.

Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.

Pandiella A, Morís F, Ocaña A, Núñez LE, Montero JC.

Oncotarget. 2015 Oct 20;6(32):32856-67. doi: 10.18632/oncotarget.5942.

3.

Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.

Bennett CN, Tomlinson CC, Michalowski AM, Chu IM, Luger D, Mittereder LR, Aprelikova O, Shou J, Piwinica-Worms H, Caplen NJ, Hollingshead MG, Green JE.

Breast Cancer Res. 2012 Jul 19;14(4):R109. doi: 10.1186/bcr3230.

4.

UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.

Gilani RA, Phadke S, Bao LW, Lachacz EJ, Dziubinski ML, Brandvold KR, Steffey ME, Kwarcinski FE, Graveel CR, Kidwell KM, Merajver SD, Soellner MB.

Clin Cancer Res. 2016 Oct 15;22(20):5087-5096. Epub 2016 May 6.

5.

Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.

Liu J, Chen X, Ward T, Pegram M, Shen K.

Tumour Biol. 2016 Jul;37(7):9825-35. doi: 10.1007/s13277-015-4650-1. Epub 2016 Jan 26.

PMID:
26810188
6.

Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.

Kai M, Kanaya N, Wu SV, Mendez C, Nguyen D, Luu T, Chen S.

Breast Cancer Res Treat. 2015 Jun;151(2):281-94. doi: 10.1007/s10549-015-3376-5. Epub 2015 Apr 23.

7.

Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.

Zheng MW, Zhang CH, Chen K, Huang M, Li YP, Lin WT, Zhang RJ, Zhong L, Xiang R, Li LL, Liu XY, Wei YQ, Yang SY.

Mol Cancer Ther. 2016 Mar;15(3):366-78. doi: 10.1158/1535-7163.MCT-15-0501. Epub 2015 Dec 31.

8.

Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors.

Serrano-Heras G, Cuenca-López MD, Montero JC, Corrales-Sanchez V, Morales JC, Núñez LE, Morís F, Pandiella A, Ocaña A.

Oncotarget. 2015 Oct 13;6(31):31272-83. doi: 10.18632/oncotarget.5211.

9.

Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.

Maia AR, de Man J, Boon U, Janssen A, Song JY, Omerzu M, Sterrenburg JG, Prinsen MB, Willemsen-Seegers N, de Roos JA, van Doornmalen AM, Uitdehaag JC, Kops GJ, Jonkers J, Buijsman RC, Zaman GJ, Medema RH.

Ann Oncol. 2015 Oct;26(10):2180-92. doi: 10.1093/annonc/mdv293. Epub 2015 Jul 7.

PMID:
26153498
10.

Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis.

Kim S, Min A, Lee KH, Yang Y, Kim TY, Lim JM, Park SJ, Nam HJ, Kim JE, Song SH, Han SW, Oh DY, Kim JH, Kim TY, Hangauer D, Lau JY, Im K, Lee DS, Bang YJ, Im SA.

Cancer Res Treat. 2017 Jul;49(3):643-655. doi: 10.4143/crt.2016.168. Epub 2016 Oct 6.

11.

Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.

Granados-Principal S, Liu Y, Guevara ML, Blanco E, Choi DS, Qian W, Patel T, Rodriguez AA, Cusimano J, Weiss HL, Zhao H, Landis MD, Dave B, Gross SS, Chang JC.

Breast Cancer Res. 2015 Feb 22;17:25. doi: 10.1186/s13058-015-0527-x.

12.

Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.

Wu YM, Chen ZJ, Liu H, Wei WD, Lu LL, Yang XL, Liang WT, Liu T, Liu HL, Du J, Wang HS.

Oncotarget. 2015 Sep 22;6(28):25588-601. doi: 10.18632/oncotarget.4436.

13.

Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.

Huang O, Zhang W, Zhi Q, Xue X, Liu H, Shen D, Geng M, Xie Z, Jiang M.

Exp Biol Med (Maywood). 2015 Apr;240(4):426-37. doi: 10.1177/1535370214554881. Epub 2014 Oct 10.

14.

Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.

Shrivastava S, Jeengar MK, Thummuri D, Koval A, Katanaev VL, Marepally S, Naidu VGM.

Biofactors. 2017 Mar;43(2):152-169. doi: 10.1002/biof.1315. Epub 2016 Sep 1.

PMID:
27580587
15.

Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer.

Arora R, Yates C, Gary BD, McClellan S, Tan M, Xi Y, Reed E, Piazza GA, Owen LB, Dean-Colomb W.

PLoS One. 2014 Jun 4;9(6):e98370. doi: 10.1371/journal.pone.0098370. eCollection 2014.

16.

Therapeutic potential of ERK5 targeting in triple negative breast cancer.

Ortiz-Ruiz MJ, Álvarez-Fernández S, Parrott T, Zaknoen S, Burrows FJ, Ocaña A, Pandiella A, Esparís-Ogando A.

Oncotarget. 2014 Nov 30;5(22):11308-18.

17.

Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.

Proia DA, Zhang C, Sequeira M, Jimenez JP, He S, Spector N, Shapiro GI, Tolaney S, Nagai M, Acquaviva J, Smith DL, Sang J, Bates RC, El-Hariry I.

Clin Cancer Res. 2014 Jan 15;20(2):413-24. doi: 10.1158/1078-0432.CCR-13-2166. Epub 2013 Oct 30.

18.

MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.

Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J, Saso H, Smith PD, Dalby KN, Ueno NT.

Mol Cancer Ther. 2015 Dec;14(12):2773-81. doi: 10.1158/1535-7163.MCT-15-0243. Epub 2015 Sep 17.

19.

Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway.

Yang B, Huang J, Xiang T, Yin X, Luo X, Huang J, Luo F, Li H, Li H, Ren G.

J Appl Toxicol. 2014 Jan;34(1):105-12. doi: 10.1002/jat.2941. Epub 2013 Oct 10.

PMID:
24122885
20.

Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.

Martin JL, de Silva HC, Lin MZ, Scott CD, Baxter RC.

Mol Cancer Ther. 2014 Feb;13(2):316-28. doi: 10.1158/1535-7163.MCT-13-0367. Epub 2013 Dec 12.

Supplemental Content

Support Center